Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14050375 | 0.93 | EGFR (0.46) | EGFRERBB2 | |
| SCHEMBL5069008 | 0.87 | EGFR (0.67) | EGFRERBB2 | |
| SCHEMBL5061417 | 0.85 | EGFR (0.56) | EGFRERBB2GAK | |
| SCHEMBL5067525 | 0.85 | EGFR (0.66) | EGFRERBB2GAK | |
| SCHEMBL5061534 | 0.84 | EGFR (0.56) | EGFRERBB2GAK | |
| SCHEMBL5061256 | 0.84 | EGFR (0.57) | EGFRERBB2GAK | |
| SCHEMBL5064685 | 0.84 | EGFR (0.54) | EGFRERBB2GAK | |
| SCHEMBL5061181 | 0.84 | EGFR (0.62) | EGFRERBB2 | |
| SCHEMBL5065393 | 0.83 | EGFR (0.55) | EGFRERBB2GAK | |
| SCHEMBL5064147 | 0.83 | EGFR (0.55) | EGFRERBB2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080269238-A1 | Thiazolopyrimidine Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1731523-A1 | THIAZOLOPYRIMIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269238-A1 | Thiazolopyrimidine Derivative | FGFR3, FGFR1, ERBB3 | EGFR 28/4885ERBB2 8/4885GAK 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.